Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLIN: ORBCEL-C for PSC and AIH
NCT02997878Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Dec 2018
- Primary completion
- Nov 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Orbcel-C in Primary Sclerosing Cholangitis (PSC), autoimmune hepatitis (AIH), sponsored by University of Birmingham. Started Dec 2018; status: active, not recruiting.
02
Drugs
Orbcel-C
03
Conditions
Primary Sclerosing Cholangitis (PSC)autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT02997878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997878.